The link between the gut microbiota, also known as the second brain, and mental health has long been studied. The idea of substances produced by the symbiotic microorganisms in the host’s gut impacting their brain, behavior, and emotions, is of vital importance. However, this link has mostly been studied in animal models rather than human-beings. Now, a study from researchers at VIB-KU Leuven identifies several gut bacteria linked to depression. The team states their findings provide further evidence that a human’s intestinal bacteria produce neurotransmitters with a potential impact on the host’s emotional well-being and mental health. The opensource study is published in the journal Nature Microbiology.
Previous studies show advances in sequencing technology enabled the exploration of the role of the gut microbiota in a broad range of neurological and psychiatric disorders and diseases. However, while these studies generated the first candidate pathology-associated taxa, they did not take into account the effects of microbiotic variables. The current study shows people suffering from depression lack two bacteria in their gut microbiota, called Coprococcus and Dialister.
The current study analyzes the gut microbiome of 1,054 people enrolled in the Flemish Gut Flora Project (FGFP). Results show two genus of bacteria, Coprococcus and Dialister, are consistently depleted in the gut microbiota of people who are diagnosed with depression. Data findings show whether they are following an antidepressant treatment has no effects on the results. These results were confirmed in a separate group of 1,063 clinically depressed participants in the Dutch LifeLines project.
The team states they also developed a computer algorithm to identify which gut bacteria may have an impact on the human nervous system and a person’s mental health. They conclude their new technology allows them to observe the ability of microorganisms to produce DOPAC, a substance linked to the neurotransmitter dopamine, associated with a healthier mental state.
The team surmises they have shown people suffering from depression lack two bacteria in their gut microbiota, called Coprococcus and Dialister. For the future, the researchers state the results of their bioinformatics analyses still needs to be confirmed in further experiments.
Source: VIB-KU Leuven
Get Healthinnovations delivered to your inbox:
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.